~~<i id='75DC1C83BC'><strike id='75DC1C83BC'><tt id='75DC1C83BC'><pre id='75DC1C83BC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

hotspot

author：hotspot 2025-10-01 00:30:29 - browse：88792

Introducing STAT’s Biotech Q2 Scorecard, our emoji-enabled means of tracking 12 make-or-break events expected over the next three months.

When each clinical trial or FDA decision crosses the wires, we’ll add in the appropriate rocket ship, grimace face, bulging bicep or broken heart — whatever captures the mood.

Read on for brief explanations of what we’re watching for from each company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Poor hospice wound care hurts patients and families

focus

leisure time

explore

leisure time

hotspot

entertainment

AdobeAfewyearsago,Iworkedwithapatientcloseto100yearsold.Shehaddiabetesformostofheradultlife,whichaff

WSS

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Anthos stroke drug appears safer than common blood thinner

Apellis safety probe of eye disease drug centers on injection needle

CRISPR pioneers react to Casgevy, first gene

Hospitals look to new technology to keep health care workers safe

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

knowledge

hotspot

focus

Guidelines to prevent youth baseball injuries need more muscle

Ransomware attacks on hospitals: Study outlines patient impact

DIEP, the 'gold standard' of breast reconstruction, is under threat

Gain of function research would be limited under House proposal

Moonlake's readout produced a cash windfall. Risks remain

A daunting task: navigating dual Medicare, Medicaid eligibility

New air purifier tech could be key to improving indoor air quality

Ransomware attacks on hospitals: Study outlines patient impact

At least 13 dead in Texas as scorching temps continue

Congress must reauthorize a committee to support older Americans

leisure time

World's first CRISPR

How to make Best Hospitals ratings actually useful for patients

Anthos stroke drug appears safer than common blood thinner

Neuroscience startup Neumora files for IPO

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

explore

leisure time

hotspot

entertainment